论文部分内容阅读
肺癌是最常见的恶性肿瘤之一,也是许多国家癌症死亡的首要原因,肺癌当中绝大多数为非小细胞肺癌(NSCLC),约占80.0%,对于晚期非小细胞肺癌(NSCLC)由于失去手术机会,而传统的化疗和放疗虽可暂时缓解症状,使肿瘤缩小,但并不能有效提高生存期,且常因放化疗的毒副反应,使患者无法耐受治疗。近年来由于新型分子靶向抗癌药物吉非替尼的出现,为晚期肺癌病人带来了新的曙光。我们于2006年9月至12月对1例晚期肺腺癌患者给予吉非替尼(iressa
Lung cancer is one of the most common malignant tumors and is the leading cause of cancer death in many countries. The majority of lung cancers are non-small cell lung cancer (NSCLC), accounting for about 80.0%. For advanced non-small cell lung cancer (NSCLC) due to loss of surgery Opportunity, while the traditional chemotherapy and radiotherapy can temporarily alleviate the symptoms, the tumor shrinks, but does not effectively improve the survival, and often due to the adverse effects of radiotherapy and chemotherapy, so that patients can not tolerate treatment. In recent years, due to the emergence of a new molecular targeted anticancer drug gefitinib, it has brought new dawn to patients with advanced lung cancer. In September 2006 to December 2006, we treated one patient with advanced lung adenocarcinoma with gefitinib (iressa